Early postnatal additional high-dose oral vitamin A supplementation versus placebo for 28 days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants
- PMID:24434948
- DOI: 10.1159/000357212
Early postnatal additional high-dose oral vitamin A supplementation versus placebo for 28 days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants
Abstract
Background: Prematurity and the associated risk for bronchopulmonary dysplasia (BPD) remain a significant threat to extremely low birth weight (ELBW) infants. Vitamin A has been considered a therapeutic alternative in reducing the rate of BPD and mortality.
Objectives: To investigate whether early postnatal, additional high-dose oral vitamin A supplementation for 28 days is more efficient in reducing BPD or death in ELBW infants than placebo treatment.
Methods: This is a multicenter, double-blind RCT comparing postnatal high-dose oral vitamin A supplementation (5,000 IU vitamin A/kg/day vs. placebo) for 28 days in ELBW neonates requiring mechanical ventilation, noninvasive ventilatory support or supplemental oxygen at 24 h of age. The primary end point is the proportion of children who died before 36 weeks' gestational age or developed moderate or severe BPD. BPD is defined as the need for supplemental oxygen to maintain SaO2 of ≥92% at rest at 36 weeks' postmenstrual age (PMA). Clinical secondary end points include the following: BPD (including mild form), intraventricular hemorrhage, periventricular leukomalacia, retinopathy of prematurity, necrotizing enterocolitis, total number of days of mechanical ventilation and oxygen supplementation, and safety and tolerability of high-dose vitamin A supplementation.
Results and conclusions: The results of the NeoVitaA trial will provide robust data with regard to the efficacy of high-dose oral vitamin A supplementation in reducing the incidence of BPD or death at 36 weeks' PMA in ELBW infants.
© 2014 S. Karger AG, Basel.
Similar articles
- Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial.Meyer S, Bay J, Franz AR, Ehrhardt H, Klein L, Petzinger J, Binder C, Kirschenhofer S, Stein A, Hüning B, Heep A, Cloppenburg E, Muyimbwa J, Ott T, Sandkötter J, Teig N, Wiegand S, Schroth M, Kick A, Wurm D, Gebauer C, Linnemann K, Kittel J, Wieg C, Kiechl-Kohlendorfer U, Schmidt S, Böttger R, Thomas W, Brevis Nunez F, Stockmann A, Kriebel T, Müller A, Klotz D, Morhart P, Nohr D, Biesalski HK, Giannopoulou EZ, Hilt S, Poryo M, Wagenpfeil S, Haiden N, Ruckes C, Ehrlich A, Gortner L; NeoVitaA trial investigators.Meyer S, et al.Lancet Respir Med. 2024 Jul;12(7):544-555. doi: 10.1016/S2213-2600(24)00073-0. Epub 2024 Apr 18.Lancet Respir Med. 2024.PMID:38643780Clinical Trial.
- Up-date on the NeoVitaA Trial: Obstacles, challenges, perspectives, and local experiences.Meyer S, Gortner L; NeoVitaA Trial investigators.Meyer S, et al.Wien Med Wochenschr. 2017 Sep;167(11-12):264-270. doi: 10.1007/s10354-016-0500-z. Epub 2016 Sep 26.Wien Med Wochenschr. 2017.PMID:27671007Clinical Trial.
- Enteral vitamin A for reducing severity of bronchopulmonary dysplasia in extremely preterm infants: a randomised controlled trial.Rakshasbhuvankar A, Patole S, Simmer K, Pillow JJ.Rakshasbhuvankar A, et al.BMC Pediatr. 2017 Dec 16;17(1):204. doi: 10.1186/s12887-017-0958-x.BMC Pediatr. 2017.PMID:29246130Free PMC article.Clinical Trial.
- Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.Bassler D.Bassler D.Neonatology. 2015;107(4):358-9. doi: 10.1159/000381132. Epub 2015 Jun 5.Neonatology. 2015.PMID:26044104Review.
- Vitamin A Supplementation for Prevention of Bronchopulmonary Dysplasia: Cornerstone of Care or Futile Therapy?Gawronski CA, Gawronski KM.Gawronski CA, et al.Ann Pharmacother. 2016 Aug;50(8):680-4. doi: 10.1177/1060028016647066. Epub 2016 May 4.Ann Pharmacother. 2016.PMID:27147702Review.
Cited by
- Prevention of bronchopulmonary dysplasia: current strategies.Jain D, Bancalari E.Jain D, et al.Zhongguo Dang Dai Er Ke Za Zhi. 2017 Aug;19(8):841-851. doi: 10.7499/j.issn.1008-8830.2017.08.001.Zhongguo Dang Dai Er Ke Za Zhi. 2017.PMID:28774356Free PMC article.
- Strategies for the prevention of bronchopulmonary dysplasia.Dini G, Ceccarelli S, Celi F.Dini G, et al.Front Pediatr. 2024 Jul 24;12:1439265. doi: 10.3389/fped.2024.1439265. eCollection 2024.Front Pediatr. 2024.PMID:39114855Free PMC article.Review.
- EARLY VITAMIN A SUPPLEMENTATION IMPROVES THE OUTCOME OF RETINOPATHY OF PREMATURITY IN EXTREMELY PRETERM INFANTS.Sun H, Cheng R, Wang Z.Sun H, et al.Retina. 2020 Jun;40(6):1176-1184. doi: 10.1097/IAE.0000000000002543.Retina. 2020.PMID:30964778Free PMC article.Clinical Trial.
- When inflammation meets lung development-an update on the pathogenesis of bronchopulmonary dysplasia.Holzfurtner L, Shahzad T, Dong Y, Rekers L, Selting A, Staude B, Lauer T, Schmidt A, Rivetti S, Zimmer KP, Behnke J, Bellusci S, Ehrhardt H.Holzfurtner L, et al.Mol Cell Pediatr. 2022 Apr 20;9(1):7. doi: 10.1186/s40348-022-00137-z.Mol Cell Pediatr. 2022.PMID:35445327Free PMC article.Review.
- Levels and effectiveness of oral retinol supplementation in VLBW preterm infants.Garofoli F, Mazzucchelli I, Decembrino L, Bartoli A, Angelini M, Broglia M, Tinelli C, Banderali G, Stronati M.Garofoli F, et al.Int J Immunopathol Pharmacol. 2018 Mar-Dec;32:2058738418820484. doi: 10.1177/2058738418820484.Int J Immunopathol Pharmacol. 2018.PMID:30897987Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical